Citizens JMP maintains Altimmune stock rating with $25 target

Citizens JMP reiterated its Market Outperform rating and $25 price target for Altimmune (ALT), citing the upcoming oral presentation of cardio-inflammatory lipidomic analyses related to pemvidutide on June 22. Altimmune's strong financial position, with more cash than debt, supports ongoing research, including the Phase 2b IMPACT data release for MASH expected this month, a key catalyst for the stock; analysts anticipate positive results from pemvidutide trials, with multiple firms maintaining bullish ratings and price targets significantly above the current trading price.

Analysis

Citizens JMP's reiteration of a Market Outperform rating and a $25 price target for Altimmune (NASDAQ: ALT), substantially above its current $5.49 trading price, underscores a positive analyst consensus, further supported by an analyst target range of $6 to $28 and five recent upward earnings revisions. This optimism is largely centered on Altimmune's lead drug candidate, pemvidutide, with an upcoming oral presentation on June 22 detailing its cardio-inflammatory lipidomic analyses; previous data has already indicated pemvidutide's efficacy in reducing lipid species linked to systemic inflammation and cardiovascular disease. A critical near-term catalyst is the anticipated release of Phase 2b IMPACT data for pemvidutide in MASH (Metabolic Associated Steatohepatitis), expected later this month, which is widely viewed as pivotal for the stock's performance. Altimmune's financial health appears robust, characterized by more cash than debt, a strong current ratio of 15.85, and a recent $35 million capital raise via an ATM facility in the first quarter of 2025, supporting its extensive research pipeline. This pipeline also includes further poster presentations on pemvidutide's impact on visceral adipose tissue and cardiovascular risk, a newly commenced Phase 2 trial for Alcohol Use Disorder (AUD), and a planned Phase 2 trial for alcohol liver disease (ALD) in the third quarter of 2025. Altimmune's reported first-quarter 2025 financial results also surpassed expectations with earnings per share of -$0.26 against an anticipated -$0.38, on $5 million in revenue. Other investment firms, including Piper Sandler (Overweight, $25 PT) and Stifel (Buy, $18 PT), share this positive sentiment, particularly regarding pemvidutide's potential in the MASH market, with topline data from the Phase 2b IMPACT trial also noted for release in the second quarter of 2025.

Key Decisions for Investors

• Investors should closely monitor the imminent release of Altimmune's Phase 2b IMPACT trial data for pemvidutide in MASH, as this is a primary near-term stock catalyst.
• Given the significant disparity between current trading levels and analyst price targets, which range up to $28, investors might consider the potential for substantial appreciation, contingent on positive clinical outcomes and mindful of the inherent risks associated with biotech development.
• Altimmune's strong liquidity position, evidenced by more cash than debt and recent capital raising, alongside its strategy to expand pemvidutide's indications into Alcohol Use Disorder and alcohol liver disease, are important factors that could mitigate development risks and broaden market opportunity.